Human urinary bladder carcinoma cell lines respond to treatment with alkylphosphocholines

Cancer Letters

Volumn 144, Issue 2, 1999, Pages 153-160

  Konstantinov, Spiro M ^a   Berger, Martin R ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Alkylphosphocholines; Apoptosis; Bladder carcinoma cells; Erucylphosphocholine; Topical treatment

Indexed keywords

ALKYL GROUP; DNA FRAGMENT; DODECYLPHOSPHORYLCHOLINE; ERUCYLPHOSPHOCHOLINE; MILTEFOSINE; OCTADECYLPHOSPHOCHOLINE; PERIFOSINE; PHOSPHORYLCHOLINE; TETRADECYLPHOSPHOCHOLINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TOPICAL TREATMENT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; DNA DAMAGE; DNA FRAGMENTATION; DNA, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTONES; HUMANS; K562 CELLS; NEOPLASM PROTEINS; PHOSPHORYLCHOLINE; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0032836892     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00219-0     Document Type: Article

References (17)

1. Eibl H., Hilgard P., Unger C. Alkylphosphocholines: new drugs in cancer therapy. Prog. Exp. Tumor Res. 1992;34.
2. Berger M.R., Muschiol C., Schmähl D., Eibl H. New cytostatics with experimentally different toxic profiles. Cancer Treat. Rev. 14:1987;307-317.
3. Hilgard P., Klenner T. Experimental pharmacology of Miltex and its constituents. Drugs Today. 30:1994;13-20.
4. Konstantinov S.M., Eibl H., Berger M.R. Alkylphosphocholines induce apoptosis in HL-60 and U-937 leukemic cells. Cancer Chemother. Pharmacol. 41:1998;210-216.
5. Konstantinov S.M., Topashka-Ancheva M., Benner A., Berger M.R. Alkylphosphocholines: effects on human leukemic cell lines and normal bone marrow cells. Int. J. Cancer. 77:1998;778-786.
6. Muschiol C., Berger M.R., Schuler B., Scherf H.R., Garzon F.T., Zeller W.J., Unger C., Eibl H., Schmähl D. Alkylphosphocholines: toxicity and anticancer properties. Lipids. 22:1987;930-934.
7. Stekar J., Hilgard P., Voegeli R., Maurer H.R., Engel J., Kutschner B., Nößner G., Schumacher W. Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133. Cancer Chemother. Pharmacol. 32:1993;437-444.
8. Unger C., Sindermann H., Peukert M., Hilgard P., Engel J., Eibl H. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer. Prog. Exp. Tumor Res. 34:1992;153-159.
9. Dummer R., Krasovec M., Röger J., Sindermann H., Burg G. Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study. J. Am. Acad. Dermatol. 29:1993;963-970.
10. Verweij J.A., Planting A., Van der Burg M., Stoter G. dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumors. J. Cancer Res. Clin. Oncol. 118:1992;606-608.
11. Unger C., Maniera T., Kaufmann-Kolle P., Eibl H. In vivo antileishmanial activity of hexadecylphosphocholines and other alkylphosphocholines. Drugs Today. 34:1998;133-140.
12. Garbe C. Maligne epitheliale Hauttumoren. Schmoll H.-J., Höffken K., Possinger K. Kompendium Internistische Onkologie. 1997;1461-1474 Springer, Berlin.
13. Schöffski P., Dunst J., Herr H.W., Höltl H., Schmoll H.-J. Harnblasenkarzinom. Schmoll H.-J., Höffken K., Possinger K. Kompendium Internistische Onkologie. 1997;1333-1374 Springer, Berlin.
14. Mossmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 139:1983;55-63.
15. Berger M.R., Sobottka S., Konstantinov S.M., Eibl H. Erucylphosphocholine is the prototype of i.v. injectable alkylphosphocholines. Drugs Today. 34:1998;73-81.
16. Unger C., Peukert M., Sindermann H. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Cancer Treat. Rev. 17:1990;243-246.
17. Planting A.S.T., Stoter G., Verweij J. Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur. J. Cancer. 29A(4):1993;518-519.